BIIB017 (peginterferon beta-1a)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Multiple Sclerosis, Relapsing-Remitting

Drug Information

Target Indication

Multiple Sclerosis, Relapsing-Remitting

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA7/18/2014

Plegridy

Treatment of relapsing remitting multiple sclerosis in adult patients.

Drug Science

Mechanism of action & safety profile

Developer

BIIB

Biogen Inc.

Related Pipeline

Muscular Atrophy, Spinal

Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

Depressive Disorder, Major

Relapsing-Remitting Multiple Sclerosis